Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market is segmented By Type of Treatment (Surgical Treatment, Pharmacological Treatment, Interve....
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market Size
Market Size in USD
CAGR7.11%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 7.11% |
| Market Concentration | High |
| Major Players | Bayer, SciPharm Sarl, Actelion Pharmaceuticals Ltd, Pfizer, United Therapeutics |
please let us know !
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market Analysis
The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Market is estimated to be valued at USD 1.41 Bn in 2024 and is expected to reach USD 2.03 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.11% from 2024 to 2031. The market is primarily driven by the increasing incidence and diagnosis rates of CTEPH disease globally. As the disease remains under-diagnosed, initiatives by governments and healthcare organizations to spread awareness are expected to boost the market during the forecast period.
The Chronic Thromboembolic Pulmonary Hypertension Market is expected to witness positive growth over the next few years. There is no standard treatment available for CTEPH currently. However, the approval and launch of new drugs to treat the disease is anticipated to provide opportunities for growth of the market. In addition, ongoing clinical trials evaluating novel drugs and treatment options for CTEPH will further aid market expansion through 2031.